Comment
doi: 10.1158/1078-0432.CCR-09-2376.
Epub 2009 Nov 24.
Do we need a different set of response assessment criteria for tumor immunotherapy?
Affiliations
- PMID: 19934296
- DOI: 10.1158/1078-0432.CCR-09-2376
Item in Clipboard
Comment
Do we need a different set of response assessment criteria for tumor immunotherapy?
Clin Cancer Res.
.
Abstract
Tumor shrinkage induced by tumor immunotherapy may be preceded by inflammatory changes. This confounds the assessment of response rates to tumor immunotherapy. In this issue of Clinical Cancer Research, Wolchok et al. attempt to address this peculiarity by proposing a new set of criteria termed immune-related response criteria.
Comment on
-
Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria.Clin Cancer Res. 2009 Dec 1;15(23):7412-20. doi: 10.1158/1078-0432.CCR-09-1624. Epub 2009 Nov 24. Clin Cancer Res. 2009. PMID: 19934295 Clinical Trial.
Similar articles
-
Multi-specific antibodies for cancer immunotherapy.BioDrugs. 2014 Aug;28(4):331-43. doi: 10.1007/s40259-014-0091-4. BioDrugs. 2014. PMID: 24638872 Review.
-
New response criteria proposed for immunotherapies.J Natl Cancer Inst. 2008 Sep 17;100(18):1280-1. doi: 10.1093/jnci/djn334. Epub 2008 Sep 9. J Natl Cancer Inst. 2008. PMID: 18780859 No abstract available.
-
Monoclonal antibodies in the treatment of malignant lymphomas.Adv Exp Med Biol. 2008;610:155-76. doi: 10.1007/978-0-387-73898-7_12. Adv Exp Med Biol. 2008. PMID: 18593022 Review. No abstract available.
-
The hazards of endpoints.J Natl Cancer Inst. 2010 Sep 22;102(18):1376-7. doi: 10.1093/jnci/djq334. Epub 2010 Sep 8. J Natl Cancer Inst. 2010. PMID: 20826734 No abstract available.
-
Federal task force seeks standards for immunotherapy biomarker studies.J Natl Cancer Inst. 2009 May 20;101(10):704-6. doi: 10.1093/jnci/djp135. Epub 2009 May 12. J Natl Cancer Inst. 2009. PMID: 19436032 No abstract available.
Cited by
-
Emerging treatments in management of prostate cancer: biomarker validation and endpoints for immunotherapy clinical trial design.Immunotargets Ther. 2013 Dec 16;3:1-8. doi: 10.2147/ITT.S30821. eCollection 2014. Immunotargets Ther. 2013. PMID: 27471695 Free PMC article. Review.
-
Nivolumab treatment beyond progressive disease in advanced non-small cell lung cancer.Clin Transl Oncol. 2021 Mar;23(3):582-590. doi: 10.1007/s12094-020-02452-1. Epub 2020 Jul 13. Clin Transl Oncol. 2021. PMID: 32661824
-
Patterns of response in patients with pretreated metastatic melanoma who received ipilimumab 3 mg/kg in a European expanded access program: five illustrative case reports.Cancer Invest. 2012 Dec;30(10):712-20. doi: 10.3109/07357907.2012.727934. Epub 2012 Oct 8. Cancer Invest. 2012. PMID: 23043499 Free PMC article.
-
Selective BRAF inhibition decreases tumor-resident lymphocyte frequencies in a mouse model of human melanoma.Oncoimmunology. 2012 Aug 1;1(5):609-617. doi: 10.4161/onci.20226. Oncoimmunology. 2012. PMID: 22934253 Free PMC article.
-
Tremelimumab: research and clinical development.Onco Targets Ther. 2016 Mar 23;9:1767-76. doi: 10.2147/OTT.S65802. eCollection 2016. Onco Targets Ther. 2016. PMID: 27042127 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
